Immuneel Therapeutics raises over Rs 100 Cr in Series B
-
Kinjal Rajpurohit
- June 8, 2026
Cancer-focused biotech startup Immuneel Therapeutics has raised over Rs 100 crore ($10.5 million) in a Series B funding round, backed by a combination of new and existing investors.
The round included participation from Singularity AMC, Rainmatter by Zerodha, and several high-net-worth individuals. Existing investors such as Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital also took part in the financing.
The Bengaluru-based company said the fresh capital will be used to expand its GMP manufacturing capabilities, accelerate the commercialization of Qartemi, strengthen its research and development pipeline, and support its expansion across the Asia-Pacific and Middle East regions.
The funding comes nearly two years after Immuneel secured Rs 100 crore ($12 million) in an extended Series A round from Taiba Middle East FZ LLC. Following that investment, the company was valued at approximately Rs 587 crore ($71 million) on a post-money basis.
Founded in 2018 by Kiran Mazumdar-Shaw, Siddhartha Mukherjee, and Kush Parwar, Immuneel develops advanced cell and gene therapies for cancer treatment. Prior to the latest round, the startup had raised more than $40 million, including a $15 million Series A round co-led by Eight Roads Ventures, True North, and F-Prime Capital in 2022.
Immuneel recently commercialized Qartemi, which it describes as India’s first approved CAR-T therapy for Non-Hodgkin Lymphoma and leukemia. The company is also advancing clinical co-development partnerships in Australia and Southeast Asia as it seeks to expand access to advanced cancer therapies in international markets.
FAQs
1. How much funding has Immuneel Therapeutics raised in its Series B round?
Immuneel Therapeutics has raised over Rs 100 crore (approximately $10.5 million) in a Series B funding round involving both new and existing investors.
2. Who participated in Immuneel’s latest funding round?
The round saw participation from Singularity AMC, Rainmatter by Zerodha, several high-net-worth individuals, and existing investors including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.
3. How will Immuneel use the fresh capital?
The company plans to use the proceeds to expand its GMP manufacturing capacity, accelerate the commercialization of Qartemi, strengthen its R&D pipeline, and support expansion across Asia-Pacific and Middle Eastern markets.
4. What is Qartemi?
Qartemi is Immuneel’s CAR-T cell therapy for cancer treatment, which the company describes as India’s first approved CAR-T therapy for Non-Hodgkin Lymphoma and leukemia.
5. What does Immuneel Therapeutics do?
Founded in 2018, Immuneel Therapeutics develops advanced cell and gene therapies for cancer treatment, with a focus on making innovative immunotherapy solutions more accessible to patients.
